- Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced new study findings based on newly established clinical thresholds on short-acting beta-agonist (SABA) use and real-world usage of ProAir Digihaler (albuterol sulfate) inhalation powder.
- ProAir Digihaler is a breath-actuated, digital SABA inhaler with built-in flow sensors that detect, record, and store objective data.
- 89% (319/359) of patients met the consensus threshold of SABA reliever medication use, and 72% (260/359) met the threshold of SABA reliever medication use ≥200% above baseline.
- Also Read: BofA Upgrades Teva Pharmaceutical On Possible Opioid Deal.
- 17% (62/359) of patients made 25 or more valid inhalations in a week, a level associated with unanimous consensus of likely impending or ongoing exacerbation.
- 29% (104/359) of the patients exhibited a rate of SABA reliever use over 12 weeks, equivalent to three or more canisters per year.
- Concurrently, Teva received the U.K. approval for Ongavia, a biosimilar to Lucentis (ranibizumab ), an eye injection, for neovascular (wet) age-related macular degeneration.
- Lucentis is marketed by Genentech, a unit of Roche Holdings AG (OTC:RHHBY).
- Price Action: TEVA shares are up 6.51% at $8.43 during the market session on the last check Tuesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks